TY - JOUR
T1 - Immunoprophylaxis of Punta Toro virus (Phlebovirus, Bunyaviridae) infection in hamsters with recombinant Eimeria profilin-like antigen
AU - Gowen, Brian B.
AU - Judge, John W.
AU - Wong, Min Hui
AU - Jung, Kie Hoon
AU - Aylsworth, Charles F.
AU - Melby, Peter C.
AU - Rosenberg, Barnett
AU - Morrey, John D.
N1 - Funding Information:
This work was supported in part by contract N01-AI-15435 from the Virology Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health.
PY - 2008/8
Y1 - 2008/8
N2 - Recombinant Eimeria antigen (rEA) has been shown to have potent anticancer and antiviral activity in respective mouse disease models, presumably through robust immune stimulation that occurs via TLR11, a pattern recognition receptor that recognizes profilin-like proteins expressed on apicomplexan protozoans. Comparable immunostimulatory activity in other species has yet to be demonstrated. Since rEA is known to be highly effective in treating Punta Toro virus (PTV) infection in mice, its ability to elicit protective immunity in the hamster PTV infection model was investigated. rEA was given alone, or in combination with IL-18 or IL-2, and virally challenged hamsters were observed for mortality. Cytokine transcript profiles for IL-12p40, IL-21, IFN-γ and TNF-α were assessed to evaluate the induction of these inflammatory mediators known to be induced in mice following exposure to rEA. A dose of 100 μg of rEA, given once 4 h prior to viral challenge, and a second time on day 3 of the infection, was found to be the most effective prophylactic therapy protecting 60% of treated hamsters from mortality, compared to only 5-10% observed in animals receiving placebo. Increased expression of IFN-γ and IL-12p40 was evident following treatment with rEA. The data suggest that rEA does induce host antiviral responses in hamsters that result in significant protection from death, although determining the most appropriate dose for intervention in other species, including humans, will likely be challenging.
AB - Recombinant Eimeria antigen (rEA) has been shown to have potent anticancer and antiviral activity in respective mouse disease models, presumably through robust immune stimulation that occurs via TLR11, a pattern recognition receptor that recognizes profilin-like proteins expressed on apicomplexan protozoans. Comparable immunostimulatory activity in other species has yet to be demonstrated. Since rEA is known to be highly effective in treating Punta Toro virus (PTV) infection in mice, its ability to elicit protective immunity in the hamster PTV infection model was investigated. rEA was given alone, or in combination with IL-18 or IL-2, and virally challenged hamsters were observed for mortality. Cytokine transcript profiles for IL-12p40, IL-21, IFN-γ and TNF-α were assessed to evaluate the induction of these inflammatory mediators known to be induced in mice following exposure to rEA. A dose of 100 μg of rEA, given once 4 h prior to viral challenge, and a second time on day 3 of the infection, was found to be the most effective prophylactic therapy protecting 60% of treated hamsters from mortality, compared to only 5-10% observed in animals receiving placebo. Increased expression of IFN-γ and IL-12p40 was evident following treatment with rEA. The data suggest that rEA does induce host antiviral responses in hamsters that result in significant protection from death, although determining the most appropriate dose for intervention in other species, including humans, will likely be challenging.
KW - Antiviral
KW - Immune modulator
KW - Phlebovirus
KW - Profilin
KW - Punta Toro virus
UR - http://www.scopus.com/inward/record.url?scp=50949096184&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=50949096184&partnerID=8YFLogxK
U2 - 10.1016/j.intimp.2008.03.019
DO - 10.1016/j.intimp.2008.03.019
M3 - Article
C2 - 18550012
AN - SCOPUS:50949096184
SN - 1567-5769
VL - 8
SP - 1089
EP - 1094
JO - International Immunopharmacology
JF - International Immunopharmacology
IS - 8
ER -